GHK-CU Powder For Promotes Wound Healing CAS:49557-75-7
The quest for effective wound healing agents has led to the discovery of bioactive peptides, among which GHK-Cu (Glycyl-L-Histidyl-L-Lysine complexed with copper) stands out. This tripeptide-copper complex, naturally occurring in human plasma, has garnered attention for its regenerative properties. Unlike conventional treatments, GHK-Cu operates at the cellular level, modulating gene expression and tissue repair. This guide delves into its structure, mechanisms, applications, and practical considerations, offering a novel synthesis of current knowledge while highlighting under-explored facets of its functionality.
What is GHK-Cu Powder?
Structure and Discovery
GHK-Cu is a tripeptide (Gly-His-Lys) bound to a copper ion, discovered in 1973 during research on human plasma albumin. The peptide's affinity for copper enhances its stability and bioavailability, making it a potent mediator of cellular processes. Copper's role as a cofactor in enzymatic reactions synergizes with the peptide's ability to activate repair pathways.
Natural Occurrence and Decline with Age
GHK-Cu is present in youthful plasma but decreases by up to 60% by age 60. This decline correlates with reduced tissue repair capacity, suggesting its critical role in maintaining homeostasis. Its exogenous application aims to restore youthful regenerative functions.
Synthesis and Formulation
Produced via solid-phase peptide synthesis, GHK-Cu powder is lyophilized for stability. It's reconstituted in sterile water or incorporated into topical formulations (creams, serums) at specific concentrations, ensuring optimal absorption.
Distinctive Features of GHK-Cu
●Molecular Precision
The peptide's small size (molecular weight ~401 Da) allows deep dermal penetration. Copper chelation prevents oxidation, prolonging activity and enhancing intracellular delivery.
●pH and Temperature Stability
GHK-Cu remains stable across a pH range of 5–8 and temperatures up to 40°C, making it suitable for diverse formulations. Unlike growth factors, it doesn't require refrigeration, easing storage.
●Dual Functionality
The complex acts as both a copper transporter and a signaling molecule. Copper ions participate in lysyl oxidase activity (collagen cross-linking), while the peptide moiety stimulates antioxidant genes like SOD1.
Applications Across Disciplines
Medical Applications
●Chronic Wounds: GHK-Cu accelerates diabetic ulcer closure by upregulating MMPs (matrix metalloproteinases) that debride necrotic tissue.
●Burn Recovery: Enhances re-epithelialization and reduces scarring via TGF-β3 modulation.
●Post-Surgical Repair: Used in post-operative care to minimize infection risk and improve tensile strength of healed tissue.
Cosmetic Innovations
●Anti-Aging: Stimulates collagen IV and VII, critical for dermal-epidermal junction integrity. A 12-week study showed 30% reduction in wrinkle depth.
●Hair Regrowth: Activates DPSCs (dermal papilla stem cells), increasing follicle size and anagen phase duration.
●Hyperpigmentation Correction: Inhibits melanocyte-stimulating hormone (α-MSH), evening skin tone.
Veterinary Use
Applied in equine and canine care for tendon injuries and post-surgical wounds, leveraging species-conserved repair mechanisms.
Research Frontiers
●Neuroprotection: Preliminary studies suggest GHK-Cu reduces amyloid-beta toxicity in Alzheimer's models.
●Oncology: Modulates angiogenesis, potentially inhibiting tumor vascularization without affecting healthy tissue.
Mechanistic Benefits
●Collagen and Elastin Synthesis
GHK-Cu binds to cellular receptors, activating MAPK/ERK pathways that upregulate collagen genes (COL1A1, COL3A1). Elastin production increases by 50% in fibroblast cultures, improving skin elasticity.
●Angiogenesis Promotion
Induces VEGF (vascular endothelial growth factor), fostering capillary growth. In ischemic wound models, GHK-Cu increased capillary density by 40% compared to controls.
●Anti-Inflammatory Action
Downregulates NF-κB, reducing IL-6 and TNF-α secretion. This mitigates chronic inflammation, a barrier to healing in diabetic wounds.
●Antimicrobial Properties
Disrupts bacterial biofilms via copper's oligodynamic effect, effective against MRSA and Pseudomonas aeruginosa at 10 μM concentrations.
●Antioxidant Defense
Chelates free copper ions, preventing Fenton reactions. Upregulates glutathione synthesis, reducing oxidative stress in irradiated keratinocytes.
Dosage and Administration
Topical Use
●Serums/Creams: 0.1–3% concentration (1–3 mg/mL). Higher concentrations (3%) for scar revision; lower (0.5%) for daily anti-aging.
●Microneedling: Combine with hyaluronic acid (1% GHK-Cu) for enhanced absorption.
Injectable Formulations
●Subcutaneous: 0.5–2 mg/kg weekly, monitored for copper overload.
●Intralesional: 1–2 mg per cm² for keloids, bi-weekly.
Oral Supplements
Limited bioavailability; enteric-coated capsules (5–10 mg/day) paired with zinc to balance metal uptake.
Cycling Recommendations
Topical Cycles
●Anti-Aging: 8 weeks on, 4 weeks off to prevent receptor desensitization.
●Acute Wounds: Continuous use until closure, then taper.
Injectable Cycles
●Musculoskeletal Repair: 6 weeks (2 mg/kg twice weekly), followed by 4-week washout.
●Hair Growth: 12-week cycle with monthly progress assessments.
Pharmacokinetics and Half-Life
Absorption and Distribution
●Topical: Peak plasma levels at 2 hours; accumulates in dermis for 72 hours.
●Subcutaneous: Tmax = 1 hour; distributes to liver, kidneys, and skin.
Half-Life
●Plasma half-life: ~2 hours. Sustained-release formulations extend activity to 8–12 hours.
●Tissue retention: Up to 48 hours in fibroblasts due to lysosomal sequestration.
Metabolism and Excretion
Degraded by peptidases into amino acids; copper excreted via bile (70%) and urine (30%).
Pharmacotoxicological and Clinical Considerations (PTC)
Toxicology Profile
●Acute Toxicity: LD50 > 500 mg/kg in rodents. No observed adverse effects at 10 mg/kg/day for 90 days.
●Mutagenicity: Negative in Ames test; no DNA adduct formation.
Clinical Trials
●Phase II (Diabetic Ulcers): 62% achieved full closure by week 12 vs. 28% placebo (n=120).
●Cosmetic Trials: 84% reported improved skin texture (double-blind, n=60).
Patient Considerations
●Contraindications: Wilson's disease, copper IUD users.
●Interactions: Avoid zinc supplements within 2 hours; antagonizes quinolone antibiotics.
Future Directions and Innovations
●Nanocarrier Delivery
Liposomal encapsulation increases dermal retention 5-fold, enhancing efficacy in alopecia models.
●Gene Editing Synergy
CRISPR-engineered fibroblasts overexpress GHK-Cu receptors, amplifying repair signals in preclinical trials.
●3D Bioprinting
Incorporated into bioinks for printing vascularized skin grafts, accelerating integration by 50%.
Clinical Data
|
Trade names |
Glycyl-L-Histidyl-L-Lysine; Growth-modulating peptide; |
|
CAS |
49557-75-7 |
|
Molar mass |
340.38 |
|
Formula |
C14H24N6O4 |
|
Purity |
Above 98% |
|
Apprarance |
Blue crystalline powder |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion
GHK-Cu represents a paradigm shift in regenerative medicine, merging peptide biology with trace element therapy. Its pleiotropic effects-from wound healing to anti-aging-underscore its versatility. As research unravels its potential in neuroprotection and oncology, GHK-Cu stands poised to redefine therapeutic strategies. Adherence to dosing guidelines and awareness of pharmacokinetic nuances ensure optimal outcomes, minimizing risks while maximizing regenerative benefits. Future innovations in delivery systems and combination therapies will likely expand its applications, cementing its role in next-generation medicine.
Hot Tags: ghk-cu powder for promotes wound healing cas:49557-75-7, China ghk-cu powder for promotes wound healing cas:49557-75-7 manufacturers, suppliers, factory
